COMMUNIQUÉS West-GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

10/09/2024 - 14:00

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the [...]

Passage Bio Welcomes Tom Kassberg to Board of Directors

10/09/2024 - 13:52

PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced [...]

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer

10/09/2024 - 13:50

BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ in prostate cancer The meeting provides a clear path towards filing an IND and [...]

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

10/09/2024 - 13:45

Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures [...]

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

10/09/2024 - 13:30

REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy [...]

Nanox to Participate in Upcoming Investor Conference in September 2024

10/09/2024 - 13:30

PETACH TIKVA, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Company management will [...]

Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer

10/09/2024 - 13:30

MORRISTOWN, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the [...]

Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight

10/09/2024 - 13:30

MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat [...]

Kura Oncology to Participate in Cantor Global Healthcare Conference

10/09/2024 - 13:30

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]

Business Insurance Honors CorVel with Two Awards in 2024

10/09/2024 - 13:15

FORT WORTH, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), a national provider of risk management solutions, today announced that it has received two awards from Business Insurance in 2024 [...]

Aveanna to Participate at the Deutsche Bank Annual Leveraged Finance Conference

10/09/2024 - 13:00

ATLANTA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Deutsche Bank Annual Leveraged Finance Conference in [...]

Lifecore Biomedical Appoints Brikkelle Thompson as Senior Vice President of Human Resources

10/09/2024 - 13:00

Ms. Thompson Brings Nearly 25 Years of HR Leadership Driving Top Performing Cultures and Building Exceptional Teams CHASKA, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore [...]

ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight

10/09/2024 - 13:00

ANN ARBOR, Mich., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today [...]

CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer

10/09/2024 - 13:00

PRESS RELEASE CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer Highly experienced dealmaker to lead CHARM’s business development and drive strategic value from CHARM’s leading protein-ligand [...]

ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference

10/09/2024 - 13:00

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, [...]

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10/09/2024 - 13:00

WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today [...]

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

10/09/2024 - 13:00

TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded work to assess additional influenza strains FORT WORTH, Texas, Sept. 10, [...]

Mural Oncology to Host First Virtual Investor Day on September 26, 2024

10/09/2024 - 13:00

Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the potential of new cytokine- [...]

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

10/09/2024 - 13:00

2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT) Favorable safety and tolerability profile with no observations of frequently [...]